ALX Oncology Announces Positive Phase 2 Trial Results for Evorpacept in HER2+ Gastric Cancer, Highlighting CD47 as Predictive Biomarker

Reuters

2025/10/03

ALX Oncology Announces Positive Phase 2 Trial Results for Evorpacept in HER2+ Gastric Cancer, Highlighting CD47 as Predictive Biomarker

ALX Oncology Holdings Inc. announced that updated data from its Phase 2 ASPEN-06 clinical trial will be presented at the upcoming Society for Immunotherapy of Cancer $(SITC)$ 40th Annual Meeting, scheduled for November 5-9, 2025. The study evaluated the company's lead therapeutic candidate, evorpacept, in combination with HERCEPTIN® (trastuzumab), CYRAMZA® (ramucirumab), and paclitaxel in patients with previously treated HER2-positive advanced gastric cancer and gastroesophageal junction cancer. The updated data will highlight CD47 overexpression as a predictive biomarker for response to evorpacept in this patient population. The poster presentation, led by Dr. Zev A. Wainberg from UCLA, is set for November 8, 2025, during the meeting's poster session.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9539394-en) on October 03, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2572500108"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572500108\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572500108?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-03 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572500108","market":"nz","top_or_hot":-1,"title":"ALX Oncology Announces Positive Phase 2 Trial Results for Evorpacept in HER2+ Gastric Cancer, Highlighting CD47 as Predictive Biomarker","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ALX Oncology Announces Positive Phase 2 Trial Results for Evorpacept in HER2+ Gastric Cancer, Highlighting CD47 as Predictive Biomarker\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ALXO\">ALX Oncology Holdings</a> Inc. announced that updated data from its Phase 2 ASPEN-06 clinical trial will be presented at the upcoming Society for Immunotherapy of Cancer <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a> 40th Annual Meeting, scheduled for November 5-9, 2025. The study evaluated the company's lead therapeutic candidate, evorpacept, in combination with HERCEPTIN® (trastuzumab), CYRAMZA® (ramucirumab), and paclitaxel in patients with previously treated HER2-positive advanced gastric cancer and gastroesophageal junction cancer. The updated data will highlight CD47 overexpression as a predictive biomarker for response to evorpacept in this patient population. The poster presentation, led by Dr. Zev A. Wainberg from UCLA, is set for November 8, 2025, during the meeting's poster session.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9539394-en) on October 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ALX Oncology Announces Positive Phase 2 Trial Results for Evorpacept in HER2+ Gastric Cancer, Highlighting CD47 as Predictive Biomarker</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nALX Oncology Announces Positive Phase 2 Trial Results for Evorpacept in HER2+ Gastric Cancer, Highlighting CD47 as Predictive Biomarker\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-03 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ALX Oncology Announces Positive Phase 2 Trial Results for Evorpacept in HER2+ Gastric Cancer, Highlighting CD47 as Predictive Biomarker\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ALXO\">ALX Oncology Holdings</a> Inc. announced that updated data from its Phase 2 ASPEN-06 clinical trial will be presented at the upcoming Society for Immunotherapy of Cancer <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a> 40th Annual Meeting, scheduled for November 5-9, 2025. The study evaluated the company's lead therapeutic candidate, evorpacept, in combination with HERCEPTIN® (trastuzumab), CYRAMZA® (ramucirumab), and paclitaxel in patients with previously treated HER2-positive advanced gastric cancer and gastroesophageal junction cancer. The updated data will highlight CD47 overexpression as a predictive biomarker for response to evorpacept in this patient population. The poster presentation, led by Dr. Zev A. Wainberg from UCLA, is set for November 8, 2025, during the meeting's poster session.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9539394-en) on October 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALXO","symbol_name":"ALX Oncology Holdings","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nNDL3cVSyG:1","article_id":"2572500108","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572500108","pubTimestamp":1759496718,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ALX Oncology Announces Positive Phase 2 Trial Results for Evorpacept in HER2+ Gastric Cancer, Highlighting CD47 as Predictive Biomarker. ALX Oncology Holdings Inc. announced that updated data from its Phase 2 ASPEN-06 clinical trial will be presented at the upcoming Society for Immunotherapy of Cancer  40th Annual Meeting, scheduled for November 5-9, 2025. The study evaluated the company's lead therapeutic candidate, evorpacept, in combination with HERCEPTIN , CYRAMZA , and paclitaxel in patients with previously treated HER2-positive advanced gastric cancer and gastroesophageal junction cancer. The updated data will highlight CD47 overexpression as a predictive biomarker for response to evorpacept in this patient population. The poster presentation, led by Dr. Zev A. Wainberg from UCLA, is set for November 8, 2025, during the meeting's poster session.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALXO":"ALX Oncology Holdings","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","NDAQ":"纳斯达克OMX交易所","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","BK4139":"生物科技","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"ALX Oncology宣布Evorpacept治疗HER2+胃癌的积极2期试验结果，强调CD47是预测性生物标志物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALXO":0.9,"NDAQ":0.9},"content_text":"ALX Oncology Announces Positive Phase 2 Trial Results for Evorpacept in HER2+ Gastric Cancer, Highlighting CD47 as Predictive Biomarker\n    \n\nALX Oncology Holdings Inc. announced that updated data from its Phase 2 ASPEN-06 clinical trial will be presented at the upcoming Society for Immunotherapy of Cancer $(SITC)$ 40th Annual Meeting, scheduled for November 5-9, 2025. The study evaluated the company's lead therapeutic candidate, evorpacept, in combination with HERCEPTIN® (trastuzumab), CYRAMZA® (ramucirumab), and paclitaxel in patients with previously treated HER2-positive advanced gastric cancer and gastroesophageal junction cancer. The updated data will highlight CD47 overexpression as a predictive biomarker for response to evorpacept in this patient population. The poster presentation, led by Dr. Zev A. Wainberg from UCLA, is set for November 8, 2025, during the meeting's poster session.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9539394-en) on October 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}